Previous 10 | Next 10 |
2024-04-23 09:30:00 ET Summary Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. In the quarter ended March 31, 2024, Baron Health Care Fund advanced 8.92% compared wi...
Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management will participate in a fireside chat at the 23rd Annual Needham Virtual Health...
Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management will participate in a fireside chat at the H.C. Wainwright 2nd Annual Cell Th...
2024-03-07 15:15:01 ET Morgan Stanley analyst issues OVERWEIGHT recommendation for ACLX on March 7, 2024 02:52PM ET. ACLX was trading at $71.94 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 3 - Buy reco...
Arcellx to Participate at the TD Cowen 44th Annual Health Care Conference PR Newswire REDWOOD CITY, Calif. , Feb. 29, 2024 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunot...
Arcellx Provides Fourth Quarter and Year-End 2023 Financial Results and Business Highlights PR Newswire -- Expanded strategic partnership with Kite -- -- Presented continued robust long-term responses from Phase 1 expansion trial of anito-cel (formerly CART-ddBCMA) in p...
2024-02-15 11:57:01 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Following a hot year of M&A with biotech stocks , we’ll see more of the same in 2024 as drug makers look to build their pipelines ahead of a massive patent cliff. Between n...
2024-02-04 17:16:46 ET More on Alnylam Pharmaceuticals, Fusion Pharmaceuticals, etc. Merus Stock: Rally Seems Overdone Alnylam's Huge Opportunity Merus: (Maybe) Building A Better Bispecific Regeneron eyes Wegovy combo to improve quality of weight loss ...
2024-01-30 05:13:34 ET Summary Arcellx is focused on engineering safer and more accessible cell therapies for cancer patients and those with incurable diseases. The company's lead product candidate, CART-ddBCMA, has shown potential as a game-changing strategy for the treatment of ...
2024-01-16 13:51:12 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biotech stocks , and the sector in general, saw a widespread beat down over the past two years. Venture capital dried up, post-pandemic healthcare landscapes shifted, and regulatory clamp...
News, Short Squeeze, Breakout and More Instantly...
2024-07-19 14:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-09 12:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...